ISMICS 2025 Annual Meeting

Seven-year experience with novel aortic bioprosthesis

Objectives: Bioprostheses are increasingly used in young patients to avoid anticoagulation. The

Inspiris Resilia aortic bioprosthesis (INSPIRIS) (Edwards Lifesciences LLC, Irvine, USA) has

shown to be extremely promising in this population, thanks to a reduced calcification of the

prosthetic leaflets in preclinical and early clinical studies. However, there is paucity of data on

patients younger than 65 years. This study investigates the hemodynamic performance and clinical

outcome of the Inspiris Resilia bioprosthesis in a group of young patients at increased risk of early

structural valve degeneration (SVD).

Methods: All the consecutive patients who received the study prosthesis from January 2018 to

October 2024 were counted: 708 patients aged 61 ± 10.9 years underwent aortic valve

replacement with the Inspiris bioprosthesis at our institution. Follow-up consisted of telephonic

interviews and in-person visits for patients with doubtful findings. The mean follow-up was 27.5 ±

21.2 months (range 1-79.9 months).

Results: 32 patients died (4.4%), 16 during the hospitalization and the other 16 after discharge.

Sixteen patients (2.2%) needed reoperation during the follow-up, only in two cases (0.3%) for an

actual degeneration. There was one case of valve thrombosis (0.1%) associated with a

thromboembolic event. A transient increase in transprosthetic gradient, in the range of subclinical

SVD, was observed in only 6 patients (0.85%). At follow-up, all but four patients reported a

significant improvement in their symptomatic status and quality of life.

Conclusions: Our study demonstrates good early hemodynamics and promising results at up to six

years in a cohort of very young patients at increased risk of SVD. Further studies with longer

follow–up are needed.

SEVEN-YEAR EXPERIENCE WITH NOVEL AORTIC BIOPROSTHESIS